Further, this investigation recapitulates the role of PARP inhibitors in the ovarian cancer population, regardless of BRCA mutational status, and underscores the need for development of relevant biomarkers that predict HR deficiency in the setting of BRCA mutations or no known genetic abnormalities. This evidence concerns the gene PARP1 and ovarian cancer.